A meibomian gland dysfunction treatment device

Abstract

This invention provides a treatment device for meibomian gland dysfunction, relating to the field of medical device technology. It addresses the technical problem that existing eyelid heating treatment devices can only achieve eyelid heating or require the administration of symptomatic medication before initiating heating treatment, failing to achieve simultaneous heating and medication action. The device includes a frame, shaped like an eyeglass frame, for the patient to wear; temples for fitting the frame around the patient's ears; a heating mechanism fixedly mounted on the frame, comprising a heating plate and heating cotton; the heating plate and heating cotton being fixedly mounted on the frame and conforming to the outer side of the patient's eyelid; and an atomizing mechanism for spraying atomized medication from the inside of the temples onto the patient's eyelid corresponding to the heating cotton. Through the eyeglass-frame-like frame, temples, and integrated heating and atomizing mechanisms, heating and medication are simultaneously administered, achieving integrated and synergistic treatment and improving efficacy.

Description

Technical Field

[0001] This invention relates to the field of medical device technology, and in particular to a treatment device for meibomian gland dysfunction. Background Technology

[0002] Meibomian gland dysfunction is a common ocular surface disease, mainly caused by blockage of the meibomian gland openings, abnormal meibomian gland secretion, and eyelid inflammation. Clinical manifestations include dry eyes, foreign body sensation, blurred vision, and eyelid burning sensation, severely impairing patients' visual quality and reducing their quality of life. Long-term development may also induce complications such as corneal damage and dry eye syndrome. Targeted treatment is needed to restore normal meibomian gland secretion function. Currently, eyelid heating therapy is the mainstream clinical intervention. Its core treatment logic is to soften viscous meibomian gland fat and relieve eyelid inflammation by heating the eyelid area, laying the foundation for the drainage of meibomian gland blockages and functional recovery.

[0003] Existing eyelid heating therapy devices have a relatively simple treatment mode, and their core function is only to heat the eyelids. They have not formed an integrated treatment structure that combines heating and medication. Although some improved devices take into account the necessity of medication-assisted treatment, they can only use a pre-treatment instillation mode. That is, before starting the heating treatment, the appropriate medication must be manually instilled into the patient's eye or on the surface of the eyelid, and then the heating operation can be performed. This cannot achieve synchronous linkage between heating and medication.

[0004] The above treatment methods have obvious limitations, resulting in poor overall treatment outcomes: On the one hand, heating alone can only soften meibomian fat and relieve mild inflammation, but it is difficult to quickly penetrate eyelid tissue and improve the microenvironment of meibomian gland secretion. For patients with moderate to severe blockage or inflammation, the efficiency of meibomian fat drainage is low, the inflammation subsides slowly, the treatment cycle is long, and the recurrence rate is high. On the other hand, the method of instilling medication first and then heating it means that the medication is easily lost due to eyelid movement and tear dilution before heating, and it cannot stay sufficiently in the meibomian gland opening and surrounding tissue, making it difficult for the medication to exert its effects of dissolving blockages, reducing inflammation, and promoting mucosal repair.

[0005] Therefore, how to overcome the limitations of existing devices in treating only one condition, achieve synchronous and coordinated heating and drug delivery, and solve the problem of poor treatment effect in simple heating or pretreatment drip mode has become a technical problem that urgently needs to be solved in the field of eyelid heating treatment devices. Summary of the Invention

[0006] The purpose of this invention is to provide a treatment device for meibomian gland dysfunction, thereby solving the technical problem that existing eyelid heating treatment devices can only achieve eyelid heating treatment or require manual instillation of symptomatic medication into the patient's eye or eyelid surface before starting the heating operation, thus failing to achieve simultaneous heating and medication action. The various technical effects of the preferred solutions among the many technical solutions provided by this invention are detailed below.

[0007] To achieve the above objectives, the present invention provides the following technical solution: A treatment device for meibomian gland dysfunction, comprising: A frame, which is shaped like an eyeglass frame, is for patients to wear; The frame has two legs, which are hinged to both sides of the frame and used to fit the frame and be worn on the patient's ear. A heating mechanism is fixedly installed on the frame. The heating mechanism includes a heating plate and heating cotton. The heating plate is fixedly installed on the frame, and the heating cotton is fixedly installed on the frame and used to fit the outer side of the patient's eyelid. The heating plate is used to release heat and transfer it to the heating cotton to heat the patient's eyelid. The atomizing mechanism is provided in two sets, which are fixedly installed on the two legs respectively. The atomizing mechanism is used to spray atomized medicine from the inside of the legs to the patient's eyelid corresponding to the heating cotton.

[0008] Furthermore, the heating mechanism also includes a PCBA control board, a heating button, and a cooling button; The PCBA control board is fixedly mounted on the frame and electrically connected to the heating plate, and is used to control the heating temperature of the heating plate; Both the heating button and the cooling button are mounted on the frame and are electrically connected to the PCBA control board. Pressing the heating button increases the release temperature of the heating plate, and pressing the cooling button decreases the release temperature of the heating plate.

[0009] Furthermore, the heating mechanism also includes a switch button, which is mounted on the frame and electrically connected to the PCBA control board. Pressing and holding the switch button can turn the heating plate on and off.

[0010] Furthermore, the heating plate includes a left eye heating plate and a right eye heating plate; The left eye heating plate is fixedly installed on the frame at the position corresponding to the patient's left eyelid, and is used to heat the patient's left eyelid; the right eye heating plate is fixedly installed on the frame at the position corresponding to the patient's right eyelid, and is used to heat the patient's right eyelid. The left eye heating plate and the right eye heating plate are electrically connected to the PCBA control board respectively; after startup, double-clicking the switch button can realize the individual heating of the left eye heating plate or the right eye heating plate.

[0011] Furthermore, each time the heating function is activated via the switch button, the left eye heating plate and the right eye heating plate heat up synchronously by default, so as to achieve a reset after a single heating mode.

[0012] Furthermore, each of the atomizing mechanisms includes a receiving box, an ultrasonic vibrating plate, and a sponge rod; The receiving box is installed on the corresponding support leg. The receiving box has a receiving cavity with a side wall opening for holding the medicine. The receiving box has multiple atomizing holes on the side facing the patient's eyelid, and each atomizing hole communicates with the receiving cavity. The ultrasonic vibrating pad is installed inside the receiving box and fits against the inner wall of the receiving box. The drug suction end of the ultrasonic vibrating pad corresponds to the inside of the receiving cavity, and the atomizing end of the ultrasonic vibrating pad corresponds to each of the atomizing holes, for atomizing the drug in the receiving cavity. The sponge rod is embedded in the receiving box, with one end of the sponge rod attached to the liquid inhalation end of the ultrasonic vibrating pad and the other end attached to the inner wall of the receiving box.

[0013] Furthermore, the atomizing mechanism also includes a lid and a spring; The lid is slidably mounted on the receiving box and is used to open or close the opening of the receiving cavity; One end of the lid is fixedly connected to a guide post, and the spring is sleeved on the guide post. One end of the spring abuts against the receiving box, and the other end abuts against the side wall of the lid. Under the elastic force of the spring, the lid slides above the opening of the receiving cavity to seal the opening. Pushing the lid can counteract the spring force to open the opening for replenishment of the medicine.

[0014] Furthermore, the atomizing mechanism also includes a ejector pin; The receiving box has a positioning hole inside, which is located inside the receiving cavity; the bottom of the receiving box has a through hole, which communicates with the receiving cavity and is located directly below the sponge rod. When in use, the sponge rod blocks the connection between the through hole and the receiving cavity. When not in use, the ejector pin is inserted into the positioning hole; when in use, the ejector pin can be inserted into the through hole to push the sponge rod out of the receiving cavity, thereby enabling the replacement of the sponge rod.

[0015] Furthermore, it also includes pressure plates and snap-on plates; The frame has a slot on the side facing the patient, and the heating plate is locked in the slot; the pressure plate is locked in the slot and presses the heating plate against the frame and the pressure plate; the buckle is fastened to the outside of the pressure plate.

[0016] A control method for a meibomian gland dysfunction treatment device, applied to the device, for controlling the coordinated operation of the heating mechanism and the nebulization mechanism of the device. The control method presets core temperature control parameters and time parameters. The core temperature control parameters include a target constant temperature value and a nebulization start-up threshold temperature, with the target constant temperature value as the upper temperature limit and the nebulization start-up threshold temperature as the lower temperature limit, constituting a heating temperature control range. The time parameters include a preset start-up duration, a preset stop duration, a preset cycle period, and a preset constant temperature maintenance duration. The control method includes three heating-nebulization coordinated control modes, which are as follows: Mode 1: After the heating mechanism heats the temperature to the target constant temperature value, the atomizing mechanism is controlled to continuously atomize the temperature. The target constant temperature value is kept constant, and the atomizing mechanism is controlled to remain open during the temperature holding period. The entire control process continues until the preset opening time ends. Mode 2: Control the heating mechanism to heat. When the heating temperature is detected to reach the atomization start threshold temperature, control the atomization mechanism to run intermittently for the preset start time and preset stop time. At the same time, continuously control the heating mechanism to finally stabilize the temperature at the target constant temperature value and maintain it. The entire control process continues until the preset treatment time ends. Mode 3: After the heating mechanism reaches the upper limit of the heating temperature control range, heating stops, and the nebulizer starts nebulization. After the temperature drops to the lower limit of the heating temperature control range, the nebulizer stops nebulization, and the heating mechanism restarts. After heating to the upper limit of the temperature range, the heating mechanism maintains a constant temperature for a preset duration, and the nebulizer starts simultaneously. The entire process of heating, maintaining a constant temperature, and cooling within the temperature range is controlled to cycle according to the preset cycle. The entire control process continues until the preset treatment duration ends.

[0017] This invention relates to a treatment device for meibomian gland dysfunction. Through a frame mimicking eyeglasses, including the temples and an integrated heating and atomization mechanism, it overcomes the shortcomings of existing devices, such as limited treatment modes, asynchronous heating and drug delivery, and low drug utilization. This integrated, synergistic treatment improves efficacy. The heating mechanism provides continuous heating against the eyelid, softening meibomian fat and relieving inflammation. The atomization mechanisms on both sides precisely spray atomized medication, simultaneously expanding the contact area with the drug. Heating enhances eyelid tissue permeability, facilitating drug penetration into the meibomian glands, preventing drug loss, and maximizing the dissolving, anti-inflammatory, and repairing effects. Attached Figure Description

[0018] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0019] Figure 1 This is a schematic diagram of the overall structure provided in an embodiment of the present invention; Figure 2 This is a schematic diagram of the framework structure provided in an embodiment of the present invention; Figure 3 This is an exploded view of the frame provided in an embodiment of the present invention; Figure 4 This is a schematic diagram of the support leg structure provided in an embodiment of the present invention; Figure 5 This is a partial cross-sectional view of the support leg structure provided in an embodiment of the present invention; Figure 6 This is a partial cross-sectional schematic diagram of the support leg structure provided in an embodiment of the present invention; Figure 7 This is a schematic diagram of a portion of the support leg structure provided in an embodiment of the present invention.

[0020] Explanation of reference numerals in the attached drawings: 100, frame; 200, support leg; 210, housing box; 220, battery box; 300, heating mechanism; 310, heating plate; 311, left eye heating plate; 312, right eye heating plate; 320, heating cotton; 330, PCBA control board; 340, heating button; 350, cooling button; 360, switch button; 370, pressure plate; 380, buckle plate; 390, adjustment button; 400, atomizing mechanism; 410, slide groove; 411, positioning groove; 412, housing cavity; 413, through hole; 414, atomizing hole; 420, box cover; 430, spring; 440, sealing cover; 460, ejector pin; 470, battery; 471, battery cover; 472, battery slot; 480, sponge rod; 490, ultrasonic vibration pad box cover. Detailed Implementation

[0021] To make the objectives, technical solutions, and advantages of this invention clearer, the technical solutions of this invention will be described in detail below. Obviously, the described embodiments are merely some embodiments of this invention, and not all embodiments. Based on the embodiments of this invention, all other implementation methods obtained by those skilled in the art without creative effort are within the scope of protection of this invention.

[0022] In the description of this invention, it should be noted that, unless otherwise stated, "a plurality of" means two or more; the terms "upper," "lower," "left," "right," "inner," "outer," "front end," "rear end," "head," "tail," etc., indicate the orientation or positional relationship based on the orientation or positional relationship shown in the accompanying drawings, and are only for the convenience of describing the invention and simplifying the description, and do not indicate or imply that the device or element referred to must have a specific orientation, or be constructed and operated in a specific orientation, and therefore should not be construed as a limitation of the invention. Furthermore, the terms "first," "second," "third," etc., are used for descriptive purposes only and should not be construed as indicating or implying relative importance.

[0023] In the description of this invention, it should also be noted that, unless otherwise explicitly specified and limited, the terms "installation," "connection," and "joining" should be interpreted broadly. For example, they can refer to a fixed connection, a detachable connection, or an integral connection; they can refer to a mechanical connection or an electrical connection; they can refer to a direct connection or an indirect connection through an intermediate medium. Those skilled in the art can understand the specific meaning of the above terms in this invention according to the specific circumstances.

[0024] The following is in conjunction with the appendix Figure 1-7 This application will be described in further detail.

[0025] Example 1 Reference Figure 1 and Figure 2 As shown, a treatment device for meibomian gland dysfunction includes a frame 100, legs 200, a heating mechanism 300, and an atomizing mechanism 400.

[0026] The frame 100 is shaped like an eyeglass frame, a design that allows for lightweight wear and quick adaptation by patients. It also distributes the overall weight of the device across the facial support area, preventing concentrated pressure on the eyeballs and eyelids. Two legs 200 are provided, hinged to both sides of the frame 100. The hinged structure allows for flexible adjustment of the opening angle to accommodate different head sizes. Together with the frame 100, this provides a convenient wearing experience similar to wearing eyeglasses, further enhancing stability and ensuring the device does not shift during treatment. Simultaneously, the remaining weight of the device is supported by the ear, completely avoiding direct structural weight impact on the ocular surface tissues.

[0027] The heating mechanism 300 is mounted on the frame 100 and positioned on one side of each eye of the patient. This design ensures that the heating area is precisely aligned with the eyelids, guaranteeing targeted treatment. The heating mechanism 300 includes a heating plate 310 and heating cotton 320, both of which are fixedly mounted on the frame 100. The heating plate 310 is located between the heating cotton 320 and the frame 100. This sandwich structure enables efficient heat conduction, allowing the heat released by the heating plate 310 to be stably transferred to the heating cotton 320, while preventing the heating plate 310 from directly contacting the eyelids and causing burns.

[0028] The frame 100 has a slot facing the side of the eyelid during patient use. The heating plate 310 is secured in the slot. A pressure plate 370 is positioned on the outer side of the heating plate 310, and the pressure plate 370 is secured in the slot to limit the heating plate 310. A buckle plate 380 is installed on the heating plate 310. A groove and a protrusion are formed between the buckle plate 380 and the pressure plate 370, and the pressure plate 370 abuts against the edge of the slot and covers the gap between the pressure plate 370 and the slot.

[0029] Heated cotton 320 is used to adhere to the outer side of the patient's eyelid. Its flexible material can adapt to the contour of the eyelid to achieve a close fit, which not only ensures uniform heat conduction to fully soften the eyelid fat, but also reduces friction and irritation to the eyelid skin, thus improving treatment comfort.

[0030] The atomizing mechanism 400 has two sets, which are respectively installed on the two support legs 200. The atomized medicine is sprayed from the inside of the support legs 200 (the opposite side of the two support legs 200) to the eyelid corresponding to the heating cotton 320. This design allows the atomized medicine to accurately cover the treatment area. Together with the heating mechanism 300, it can achieve synergistic treatment of heating and softening and atomization-assisted fat removal. It not only replaces the traditional heavy pneumatic pressing module, reducing the weight burden of the device, but also moisturizes the eyelid margin with atomized medicine, helps to remove obstructing foreign objects, and achieves anti-inflammatory care, thus improving the treatment effect.

[0031] Example 2 Reference Figure 2 and Figure 3As shown, this embodiment further defines the heating mechanism 300. In this embodiment, the heating mechanism 300 further includes a PCBA control board 330, a heating button 340, a cooling button 350, and a switch button 360. The top of the frame 100 (i.e., the top in the wearing state) has a recess for placing the PCBA control board 330. The PCBA control board 330 is embedded and installed in the recess. This embedding design allows for concealed installation of the PCBA control board 330, avoiding the occupation of extra space, while reducing the overall thickness and weight of the device, further improving the lightweight effect. A cover plate is fitted inside the recess to confine the PCBA control board 330 within the recess. The cover plate provides stable protection for the PCBA control board 330, preventing dust and medication from seeping in and causing circuit failures during treatment, and also ensures the frame 100 has a flat appearance, improving wearing comfort.

[0032] The heating button 340, cooling button 350, and switch button 360 are all mounted on the cover plate on the frame 100 and are electrically connected to the PCBA control board 330 to control the PCBA control board 330. The heating button 340 and cooling button 350 are symmetrically arranged on both sides of the switch button 360. This layout conforms to ergonomic operating habits, making it easy for patients to quickly distinguish and accurately operate, reducing the difficulty of use and improving the convenience of use.

[0033] The specific control logic is as follows: Pressing and holding the switch button 360 turns the heating plate 310 on and off. The operation is simple and intuitive, allowing patients to control the start and stop of treatment independently. Pressing the heating button 340 increases the release temperature of the heating plate 310, and pressing the cooling button 350 decreases the release temperature of the heating plate 310. Through precise temperature control via dual buttons, it can adapt to the different eye tolerance and treatment needs of different patients, avoiding excessively high temperatures that may cause eye burns or excessively low temperatures that may affect the softening effect of the eyelid fat, thus ensuring the safety and effectiveness of the treatment.

[0034] Example 3 This embodiment further defines the heating mechanism 300. The basic structure of the device is the same as that of the previous embodiment, and will not be described again here.

[0035] Reference Figure 2 and Figure 3 As shown, in this embodiment, the heating plate 310 further includes a left eye heating plate 311 and a right eye heating plate 312. The left eye heating plate 311 is fixedly installed on the frame 100 at the position corresponding to the patient's left eyelid, and the right eye heating plate 312 is fixedly installed on the frame 100 at the position corresponding to the patient's right eyelid. This separate design can achieve precise alignment of the heating areas of both eyes, ensuring that the heat only acts on the target eyelid, avoiding energy waste, and at the same time adapting to the targeted treatment needs of patients with unilateral disease, improving treatment flexibility.

[0036] The left eye heating plate 311 and the right eye heating plate 312 are electrically connected to the PCBA control board 330, respectively. This independent electrical connection structure provides the circuit basis for independent or simultaneous heating of both eyes, and the heating mode can be flexibly switched through control logic. The specific control rules are as follows: After activation, double-clicking the switch button 360 can realize the individual heating of the left eye heating plate 311 or the right eye heating plate 312, which is convenient for patients to accurately adjust according to the discomfort symptoms of one eye, reduce unnecessary heating stimulation of healthy eyelids, and improve treatment comfort. Each time the heating function is turned on by the switch button 360, the left eye heating plate 311 and the right eye heating plate 312 are heated simultaneously by default. This default setting can realize automatic reset after a single heating mode, and can restore the standard treatment mode without additional operation, simplifying the operation process, reducing the difficulty of use, and ensuring the consistency and effectiveness of treatment for patients with bilateral diseases.

[0037] Example 4 This embodiment further defines the atomizing mechanism 400. The basic structure of the device is the same as that of the previous embodiment, and will not be described again here.

[0038] Reference Figure 4 and Figure 5 As shown, in this embodiment, the atomizing mechanism 400 further includes a receiving box 210, an ultrasonic vibrating plate, a sponge rod 480, and a ejector pin 460.

[0039] The receiving box 210 is fixedly mounted on the support leg 200, or integrated with the support leg 200. Both mounting methods improve the stability of the connection between the nebulizing mechanism 400 and the support leg 200, preventing the nebulization direction from shifting due to device shaking during treatment. Simultaneously, the hinge point between the support leg 200 and the frame 100 is located at the side wall edge of the receiving box 210 and the frame 100. This hinge position design allows for precise adjustment of the orientation of the receiving box 210, ensuring that the nebulizing mechanism 400 always corresponds to the eyelid area during patient use, guaranteeing accurate coverage of the treatment site with the nebulized medication and enhancing the synergistic treatment effect.

[0040] The container 210 has a receiving cavity 412 with an opening at the top for holding the medication. The top opening design facilitates quick replenishment of the medication, improving ease of use. The container 210 has multiple atomizing holes 414 on the side facing the patient's eyelid. Each atomizing hole 414 communicates with the receiving cavity 412. The multiple atomizing holes 414 layout expands the atomization coverage area, allowing the medication to act evenly on the eyelid and eyelid margin area, enhancing the targeted nature of the treatment.

[0041] The ultrasonic vibrating pad is installed inside the receiving cavity 412 and fits against the inner wall of the receiving box 210. Its liquid inhalation end corresponds to the inside of the receiving cavity 412 and its atomizing end corresponds to each atomizing hole 414. This installation posture can ensure atomization efficiency, so that the ultrasonic vibrating pad can stably atomize the liquid in the receiving cavity 412 into fine particles, which are easy for the eyelid and eyelid margin tissue to absorb.

[0042] The sponge rod 480 is embedded in the receiving box 210, with one end attached to the liquid inhalation end of the ultrasonic vibrating pad and the other end attached to the inner wall of the receiving box 210. The sponge rod 480 can absorb and store the liquid, avoiding liquid accumulation and leakage caused by direct contact between the liquid and the ultrasonic vibrating pad. At the same time, it can continuously and stably supply liquid to the ultrasonic vibrating pad, ensuring that the nebulization process is continuous and uninterrupted. When in use, the ultrasonic vibrating pad absorbs the liquid in the sponge rod 480 and vibrates it into a mist, which is then sprayed out through the nebulization hole 414 to reach the patient's eyelid, realizing a continuous function of stable liquid supply, efficient nebulization, and precise delivery.

[0043] The ultrasonic vibrating pad is electrically connected to the PCBA control board 330. When the switch button 360 is turned on, the ultrasonic vibrating pad starts; when the switch button 360 is turned off, the ultrasonic vibrating pad stops.

[0044] Reference Figure 5 and Figure 6 As shown, a positioning hole is provided in the receiving box 210. The positioning hole is located inside the receiving cavity 412 and is used to place the ejector pin 460. The positioning hole can limit the ejector pin 460 to prevent it from being lost or misplaced, and improve the convenience of device accessory management.

[0045] The bottom of the container 210 is provided with a through hole 413, which is connected to the container cavity 412 and located directly below the sponge rod 480. During use, the sponge rod 480 can naturally block the connection between the through hole 413 and the container cavity 412, preventing the liquid medicine in the container cavity 412 from leaking out of the through hole 413 and ensuring the airtightness of the liquid medicine storage.

[0046] When the sponge rod 480 needs to be replaced, the ejector pin 460 can be inserted into the through hole 413 from the bottom of the receiving box 210 to push the sponge rod 480 out from the receiving cavity 412. This ejection replacement structure does not require disassembling the receiving box 210, making the operation simple and quick. It can effectively reduce the difficulty of replacing the sponge rod 480, and at the same time avoid damage to precision parts such as ultrasonic vibrating pads during the replacement process, thus improving the convenience of device maintenance and service life.

[0047] Example 5 This embodiment further defines the atomizing mechanism 400. The basic structure of the device is the same as that of the previous embodiment, and will not be described again here.

[0048] Reference Figure 6 and Figure 7As shown, in this embodiment, the atomizing mechanism 400 further includes a cover 420, a spring 430, and a sealing cover 440.

[0049] The top of the receiving box 210 is provided with a sliding groove 410, which is located on the top of the receiving cavity 412 and communicates with it. The sliding groove 410 provides a stable sliding guide for the lid 420, ensuring that the opening and closing movement of the lid 420 is precise and controllable, and avoiding deviation and jamming. The lid 420 is slidably disposed in the sliding groove 410 along the extension direction of the sliding groove 410. A guide post is fixedly connected to one end of the lid 420, and a spring 430 is sleeved on the guide post. One end of the spring 430 abuts against the connection between the guide post and the lid 420, and the other end abuts against the side wall of the sliding groove 410.

[0050] This elastic connection structure, aided by the restoring force of the spring 430, drives the lid 420 to automatically slide along the groove 410 to the opening of the receiving cavity 412 and achieve a seal, eliminating the need for manual locking. This simplifies the operation process and ensures the reliability of the seal at the opening of the receiving cavity 412, preventing evaporation or leakage of the medicine and guaranteeing the stability of medicine storage. When medicine needs to be replenished, simply pushing the lid 420 will counteract the spring force of the spring 430 and open the opening, making the operation convenient, efficient, and improving the ease of medicine replenishment.

[0051] The top of the receiving box 210 is also provided with a positioning groove 411, which is located above the slide groove 410. The sealing cover 440 is embedded in the positioning groove 411. The matching design of the positioning groove 411 and the sealing cover 440 provides a convenient assembly positioning reference for the assembly of the atomizing mechanism 400: during assembly, the sealing cover 440 can be opened first, the box cover 420 can be slidably installed in the slide groove 410, the spring 430 can be installed in the slide groove 410 (i.e., below the positioning groove 411) and abut against the side wall of the slide groove 410, and finally the sealing cover 440 can be embedded back into the positioning groove 411 to complete the assembly.

[0052] The sealing cap 440 provides axial support for the spring 430 and the box cover 420, effectively preventing the spring 430 from loosening and the box cover 420 from disengaging from the slide groove 410, ensuring the overall stability of the atomizing mechanism 400 and extending the service life of the device.

[0053] Example 6 Reference Figure 6 and Figure 7 As shown, this embodiment defines the driving source for the meibomian gland dysfunction treatment device.

[0054] A battery box 220 is installed on the support leg 200. The battery box 220 can be integrated with the housing box 210. This integrated design can simplify the device structure, reduce the number of parts, reduce the overall size and weight of the device, further improve the lightweight effect, and avoid the problem of loose connection caused by separate installation of the battery box 220 and the housing box 210.

[0055] The battery box 220 includes a battery slot 472 formed on the side of the receiving box 210 away from the frame 100, and a battery cover 471 installed in the battery slot 472. A rechargeable battery 470 is installed in the battery slot 472. The layout of the battery slot 472 avoids the receiving cavity 412 and the nebulizer assembly, preventing the battery 470 from contacting the liquid medicine and improving the safety of use. The rechargeable battery 470 can be reused, reducing the cost of use for patients.

[0056] The battery 470 is electrically connected to the ultrasonic vibrating plate and the PCBA control board 330 respectively, providing stable power to both and ensuring the continuous and stable operation of the temperature control function of the heating mechanism 300 and the nebulization function of the nebulization mechanism 400. The wiring can be routed through the legs 200 and the frame 100, eliminating the need for an external power cord, thus improving the portability of the device and adapting it to various scenarios such as home treatment for patients.

[0057] Example 7 A control method for a treatment device for meibomian gland dysfunction is provided, which controls the linkage operation of the heating mechanism (300) and the atomizing mechanism (400) of the device. A Bluetooth control module is installed on the PCBA control board (330), and an adjustment button (390) for adjusting different modes is provided on the cover. The adjustment button (390) is electrically connected to the PCBA board and can switch between three collaborative control modes by manual pressing. Simultaneously, the Bluetooth control module supports remote adjustment of temperature and time parameters.

[0058] The control method presets core temperature control parameters and time parameters, with the following preferred settings for each parameter: Core temperature control parameters include a target constant temperature value and an atomization initiation threshold temperature. Preferably, the target constant temperature value is set to 42.5℃, and the atomization initiation threshold temperature is set to 38℃. Using the target constant temperature value as the upper temperature limit and the atomization initiation threshold temperature as the lower temperature limit, a heating temperature control range of 38℃-42.5℃ is formed. Time parameters include preset on-time duration, preset off-time duration, preset cycle time, and preset constant temperature maintenance duration. Preferably, the preset on-time and preset off-time durations are both set to 5 seconds, the preset cycle time is set to 30 seconds, the preset constant temperature maintenance duration is set to 5-8 seconds, and the preset treatment time is set to 15 minutes. These preferred parameters are suitable for the physiological characteristics of the meibomian glands and the drug absorption patterns of most patients, effectively improving the treatment effect.

[0059] The control method includes three coordinated control modes for heating and atomization, which are as follows: Mode 1: After the heating mechanism (300) heats to the target constant temperature (suitable for meibomian gland softening), the atomizing mechanism (400) is controlled to continuously atomize. The target constant temperature is preferably 42.5℃. This temperature range accurately matches the meibomian gland softening requirements, effectively reducing meibomian gland viscosity, breaking down the blockage structure at the meibomian gland opening, creating favorable conditions for meibomian gland discharge, and avoiding excessive temperature that could burn the eyelid skin and ocular surface mucosa. At the same time, it avoids the problem of insufficient meibomian gland softening and difficulty in discharging blockages due to insufficient temperature. The target constant temperature is kept constant, and the atomizing mechanism (400) is continuously turned on during the temperature maintenance period. The entire control process continues until the preset on-time (i.e., preset treatment time) ends. The preset treatment time is preferably 15 minutes. This time ensures that the meibomian gland is fully softened and the atomized medicine is fully penetrated, avoiding poor results due to short treatment time, while avoiding eye fatigue and discomfort caused by long-term treatment, and achieving a balance between treatment effect and comfort.

[0060] Mode 2: Control the heating mechanism (300) to heat. When the heating temperature is detected to reach the atomization start threshold temperature (suitable for drug absorption), control the atomization mechanism (400) to run intermittently according to the preset start time and preset stop time. At the same time, continuously control the heating mechanism (300) to finally stabilize the temperature at the target constant temperature value and maintain it. The entire control process continues until the preset treatment time ends.

[0061] The preferred atomization activation threshold temperature is 38℃, which is the optimal temperature range for efficient drug absorption. When the eyelid temperature reaches 38℃, the permeability of the stratum corneum of the eyelid skin increases, and the blood circulation of the eyelid margin tissue accelerates, which can promote the rapid penetration of the atomized drug into the meibomian glands and the inflamed areas of the eyelid margin. This significantly enhances the anti-inflammatory, blockage-dissolving, and mucosal repair effects of the drug. Compared with the problem of slow drug absorption and low utilization rate in low-temperature environments, this threshold temperature setting can improve the absorption efficiency of the drug.

[0062] The target constant temperature is preferably 42.5℃. While the drug solution penetrates, it continuously softens the meibomian fat, achieving the dual effects of anti-inflammatory and meibomian fat softening. The atomizing mechanism (400) operates intermittently at a preferred rhythm of 5 seconds on and 5 seconds off. This avoids eye irritation caused by excessive accumulation of drug solution due to continuous atomization, while ensuring continuous replenishment of drug solution and maintaining a stable local drug solution concentration in the eye, further enhancing the treatment effect. The preset treatment time is preferably 15 minutes, which can ensure that the inflammation is effectively relieved and the blockage is gradually dissolved, adapting to the treatment needs of mild to moderate meibomian gland dysfunction.

[0063] Mode 3: Control the heating mechanism (300) to heat to the upper limit of the heating temperature control range (i.e., the target constant temperature value) and then stop heating, and control the atomizing mechanism (400) to start atomization; after the detected temperature drops to the lower limit of the heating temperature control range (i.e., the atomization start threshold temperature), control the atomizing mechanism (400) to stop atomization and restart the heating mechanism (300) to heat.

[0064] The heating temperature control range is adapted to both meibomian gland softening and drug absorption. The preferred heating temperature control range of 38℃-42.5℃ can achieve synergistic optimization of meibomian gland softening and drug absorption. When the temperature is at the upper limit of the range of 42.5℃, the focus is on softening meibomian glands to provide support for the discharge of blockages. When the temperature drops to the lower limit of the range of 38℃, the focus is on drug absorption to improve the utilization efficiency of the drug. The cyclical temperature control can take into account both therapeutic effects. Compared with single temperature control, it is more suitable for complex meibomian gland lesions.

[0065] After heating to the upper limit of the temperature range, the heating mechanism (300) is controlled to maintain a constant temperature for a preset duration (preferably 5-8 seconds), and the atomizing mechanism (400) is activated simultaneously. This constant temperature maintenance duration ensures that the meibomian gland fat is fully softened, while allowing sufficient time for the atomized medication to penetrate, avoiding a sudden drop in temperature that could affect the softening effect of the meibomian gland fat. The entire process of heating, maintaining a constant temperature, and cooling within this temperature range is controlled by a temperature control algorithm to cycle according to a preset cycle (preferably 30 seconds). The preset cycle is optimized to match the temperature switching rhythm with the physiological rhythm of meibomian gland fat softening and medication absorption, avoiding eye discomfort caused by excessively rapid temperature fluctuations, while ensuring that the treatment process is stable and controllable. The entire control process continues until the preset treatment time (preferably 15 minutes) ends, making it suitable for patients with severe meibomian gland obstruction and significant eyelid inflammation, achieving a comprehensive treatment effect of draining the obstruction, relieving inflammation, and repairing the mucosa.

[0066] Among them, mode one is activated by pressing the adjustment button (390) once, mode two is activated by pressing the adjustment button (390) for a long time (preferably for a pressing time of ≥3s), and mode three is activated by pressing the adjustment button (390) twice in succession (with an interval of ≤1s between the two pressings). The operation logic is simple and easy to understand, suitable for patients of different ages, and can effectively avoid mode switching caused by misoperation, thus improving the ease of use of the device.

[0067] The above description is merely a specific embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any variations or substitutions that can be easily conceived by those skilled in the art within the scope of the technology disclosed in the present invention should be included within the scope of protection of the present invention. Therefore, the scope of protection of the present invention should be determined by the scope of the claims.

Claims

1. A treatment device for meibomian gland dysfunction, characterized in that, include: A frame (100), the frame (100) being in the shape of an eyeglass frame, for use by a patient; The frame leg (200) has two parts, which are respectively hinged to both sides of the frame (100) and used to fit the frame (100) to be worn on the patient's ear; A heating mechanism (300) is fixedly installed on the frame (100). The heating mechanism (300) includes a heating plate (310) and heating cotton (320). The heating plate (310) is fixedly installed on the frame (100), and the heating cotton (320) is fixedly installed on the frame (100) and used to fit the outer side of the patient's eyelid. The heating plate (310) is used to release heat and transfer it to the heating cotton (320) to heat the patient's eyelid. The atomizing mechanism (400) is provided in two sets, which are fixedly installed on the two legs (200) respectively. The atomizing mechanism (400) is used to spray atomized medicine from the inside of the legs (200) to the patient's eyelid corresponding to the heating cotton (320).

2. The treatment device for meibomian gland dysfunction according to claim 1, characterized in that, The heating mechanism (300) also includes a PCBA control board (330), a heating button (340), and a cooling button (350). The PCBA control board (330) is fixedly installed on the frame (100) and electrically connected to the heating plate (310) for controlling the heating temperature of the heating plate (310); The heating button (340) and the cooling button (350) are both mounted on the frame (100) and are electrically connected to the PCBA control board (330). Pressing the heating button (340) can increase the release temperature of the heating plate (310), and pressing the cooling button (350) can decrease the release temperature of the heating plate (310).

3. The meibomian gland dysfunction treatment device according to claim 2, characterized in that, The heating mechanism (300) also includes a switch button (360), which is mounted on the frame (100) and electrically connected to the PCBA control board (330). Pressing and holding the switch button (360) can turn the heating plate (310) on and off.

4. The meibomian gland dysfunction treatment device according to claim 3, characterized in that, The heating plate (310) includes a left eye heating plate (311) and a right eye heating plate (312); The left eye heating plate (311) is fixedly installed on the frame (100) at the position corresponding to the patient's left eyelid and is used to heat the patient's left eyelid; the right eye heating plate (312) is fixedly installed on the frame (100) at the position corresponding to the patient's right eyelid and is used to heat the patient's right eyelid. The left eye heating plate (311) and the right eye heating plate (312) are electrically connected to the PCBA control board (330), respectively. After startup, double-clicking the switch button (360) can enable individual heating of the left eye heating plate (311) or the right eye heating plate (312).

5. The meibomian gland dysfunction treatment device according to claim 4, characterized in that, Each time the heating function is turned on by the switch button (360), the left eye heating plate (311) and the right eye heating plate (312) are heated synchronously by default to achieve a reset after a single heating mode.

6. The meibomian gland dysfunction treatment device according to claim 1, characterized in that, Each of the atomizing mechanisms (400) includes a receiving box (210), an ultrasonic vibrating plate, and a sponge rod (480). The receiving box (210) is installed on the corresponding support leg (200). The receiving box (210) has a receiving cavity (412) with a side wall opening. The receiving cavity (412) is used to hold the medicine liquid. The receiving box (210) has a plurality of atomizing holes (414) on the side facing the patient's eyelid. Each of the atomizing holes (414) is connected to the receiving cavity (412). The ultrasonic vibrating pad is installed inside the receiving box (210) and adheres to the inner wall of the receiving box (210). The drug suction end of the ultrasonic vibrating pad corresponds to the inside of the receiving cavity (412), and the atomizing end of the ultrasonic vibrating pad corresponds to each of the atomizing holes (414), which is used to atomize the drug in the receiving cavity (412). The sponge rod (480) is embedded in the container (210), with one end of the sponge rod (480) attached to the liquid inhalation end of the ultrasonic vibrating plate and the other end attached to the inner wall of the container (210).

7. The meibomian gland dysfunction treatment device according to claim 6, characterized in that, The atomizing mechanism (400) also includes a cover (420) and a spring (430); The lid (420) is slidably mounted on the receiving box (210) for opening or closing the opening of the receiving cavity (412); One end of the lid (420) is fixedly connected to a guide post, and the spring (430) is sleeved on the guide post. One end of the spring (430) abuts against the receiving box (210), and the other end abuts against the side wall of the lid (420). Under the elastic force of the spring (430), the lid (420) slides above the opening of the receiving cavity (412) to seal the opening. Pushing the lid (420) can counteract the elastic force of the spring (430) to open the opening for replenishment of medicine.

8. The meibomian gland dysfunction treatment device according to claim 6, characterized in that, The atomizing mechanism (400) also includes a pin (460); The receiving box (210) has a positioning hole inside, which is located inside the receiving cavity (412); the bottom of the receiving box (210) has a through hole (413), which communicates with the receiving cavity (412) and is located directly below the sponge rod (480). When in use, the sponge rod (480) blocks the communication between the through hole (413) and the receiving cavity (412). When not in use, the ejector pin (460) is inserted into the positioning hole; when in use, the ejector pin (460) can be inserted into the through hole (413) to push the sponge rod (480) out of the receiving cavity (412) so as to replace the sponge rod (480).

9. The treatment device for meibomian gland dysfunction according to claim 1, characterized in that, It also includes a pressure plate (370) and a snap-on plate (380); The frame (100) has a slot on the side facing the patient, and the heating plate (310) is locked in the slot; the pressure plate (370) is locked in the slot and presses the heating plate (310) against the frame (100) and the pressure plate (370); the buckle plate (380) is snapped onto the outside of the pressure plate (370).

10. A control method for a treatment device for meibomian gland dysfunction, characterized in that, The device for treating meibomian gland dysfunction according to any one of claims 1-9 is used to control the linkage operation of the heating mechanism (300) and the nebulization mechanism (400) of the device. The control method presets core temperature control parameters and time parameters. The core temperature control parameters include a target constant temperature value and a nebulization start-up threshold temperature, with the target constant temperature value as the upper temperature limit and the nebulization start-up threshold temperature as the lower temperature limit, constituting a heating temperature control range. The time parameters include a preset start-up duration, a preset stop duration, a preset cycle period, and a preset constant temperature maintenance duration. The control method includes three heating-nebulization coordinated control modes, which are as follows: Mode 1: After the heating mechanism (300) heats to the target constant temperature value, the atomizing mechanism (400) is controlled to continuously atomize; the target constant temperature value is kept constant, and the atomizing mechanism (400) is controlled to be continuously turned on during the temperature maintenance period. The entire control process continues until the preset on time ends. Mode 2: Control the heating mechanism (300) to heat. When the heating temperature is detected to reach the atomization start threshold temperature, control the atomization mechanism (400) to run intermittently according to the preset start time and preset stop time. At the same time, continuously control the heating mechanism (300) to finally stabilize the temperature at the target constant temperature value and maintain it. The entire control process continues until the preset treatment time ends. Mode 3: Control the heating mechanism (300) to heat to the upper limit of the heating temperature control range and then stop heating, and control the nebulization mechanism (400) to start nebulization; after the detected temperature drops to the lower limit of the heating temperature control range, control the nebulization mechanism (400) to stop nebulization and restart the heating mechanism (300) to heat; after heating to the upper limit of the temperature range, control the heating mechanism (300) to maintain the constant temperature for the preset duration, and simultaneously start the nebulization mechanism (400), and control the entire process of heating, maintaining constant temperature, and cooling within the temperature range to cycle according to the preset cycle period, and the entire control process continues until the preset treatment time ends.

Images